Vitasoy International Holdings Limited

Window: FY2022–FY2026 (FY2021 shown in select tables for pre-boycott reference). Sources: annual results announcements FY2021–FY2026; AR 2024/25 financial highlights and five-year chart data.

Income statement

Notes: FY2022 EPS derived (loss ÷ ~1.064bn weighted shares) — not company-reported in sources reviewed. FY2021 reference: revenue 7,520; GP 3,954; OP 843; EBITDA 1,281; PBT 767; attributable profit 548; DPS 32.8.

Margins and growth

Revenue CAGR FY2022–FY2026: −1.7% (derived); FY2021–FY2026: −4.2% (derived).

Commentary. The five-year arc has three phases. (1) Shock (FY2022): the July 2021 boycott removed products from Mainland shelves during peak summer; Mainland revenue fell 23% in HK$ and swung to a HK$340m operating loss, producing the Group's first loss since 1994. (2) Repair (FY2023–FY2025): with flat-to-down revenue, management rebuilt margins through Mainland rightsizing, pricing, lower commodity costs and a "more efficient manufacturing footprint" (AR 2024/25). Gross margin expanded ~410bp and opex fell from HK$3,010m (FY2024) to HK$2,930m (FY2025); profit doubled in each of FY2024 and FY2025. (3) Plateau (FY2026): revenue fell 3% as Mainland general trade weakened and Macau/Vitaland underperformed; underlying OP rose only 4% to HK$377m, and adjusted attributable profit fell 4% to HK$225m. Headline growth (+17%) was flattered by the HK$151m Shanghai land gain, partly offset by the HK$98m Australia impairment and a higher tax charge (write-off of VAP deferred tax assets; ETR 30%). The inflection to watch is whether gross margin (51%) can hold as trade-promotion intensity rises in Mainland.

Balance sheet

Notes: intangibles are de minimis (HK$17k at FY2026). Net cash = cash less bank borrowings, bills payable and lease liabilities. FY2026 cash currency mix: 65% HKD, 22% RMB, 8% AUD, 2% USD. Undrawn facilities HK$1,230m (FY2026).

Commentary. The balance sheet has been transformed. Net current liabilities of HK$475m at March 2022 (when the board had to justify going-concern on facility headroom) have become net current assets of HK$575m. Bank debt is modest (HK$258m, all short-term), and the group carried HK$703m net cash at March 2026 despite HK$418m of buy-backs. Equity fell HK$182m in FY2026 because buy-backs and dividends exceeded profit — an intentional capital-return choice.

Cash flow

Sources: OCF, cash capex and FCF from StockAnalysis (aggregator; not reconciled to the audited cash-flow statement); capex incurred from company reports; dividends paid derived from note 8 (FY2026: HK$107.0m prior final + HK$41.2m interim; FY2025: HK$67.5m + HK$42.9m).

Commentary. FCF conversion is strong (FY2026 FCF ≈ 2.0× adjusted attributable profit) because depreciation (HK$480m) materially exceeds maintenance capex after the heavy Dongguan build (FY2022 cash capex HK$410m). The FY2026 OCF decline reflects working-capital absorption (other receivables up HK$133m, including disposal-related items). Capital allocation has shifted decisively toward shareholder returns: FY2026 distributions (dividends + buy-backs ≈ HK$566m) roughly equalled FCF.

Ratios

All ratios except ROCE and gearing are derived. Payable days exclude accrued expenses (HK$1,018m) and sales-rebate payables (HK$384m); including them would turn the CCC sharply negative, reflecting strong bargaining power with suppliers and customers. ROIC is not disclosed; company ROCE is the closest proxy.

Management guidance (FY2027)

Qualitative only: expand the business and increase revenue growth while maintaining efficiency; Mainland "step change" in commercial execution under new sales leadership; HK scale leadership via innovation and Macau rebuild; ANZ and Singapore sales growth with better profitability; Philippines improvement from 2027; proactive cost controls versus rising oil-related costs.

Consensus

Third-party target range HK$7.00–11.66 implies limited upside at the consensus midpoint (~6% to HK$7.20).

Bull case

1. Operating leverage on recovery: with 51% gross margin and opex already cut 5%, every 1% of Mainland revenue recovery (~HK$32m) drops disproportionately to OP; 2H FY2026 improvement suggests the sales reset is working.

2. Australia inflection: underlying ANZ loss already narrowed to AUD8m; the impairment lowers depreciation, and breakeven would add ~HK$40m to OP (~10% of FY2026 underlying OP).

3. Strategic optionality and capital return: a 20% holder with a related beverage company, net cash of HK$703m and an active buy-back (≈10% mandate) provide downside support and potential takeover/collaboration upside at ~7x EV/EBITDA.

Bear case

1. Structural Mainland erosion: general trade is declining and Vitasoy is sub-scale against Tingyi, Nongfu and Uni-President in tea; FY2026 Mainland revenue fell 7% in local currency.

2. Earnings quality: adjusted attributable profit fell 4% in FY2026; ~31x adjusted P/E is demanding for a no-growth staple.

3. Event risks: unquantified Mainland tax enquiry, cost inflation, and boycott-type reputational risk, plus a potentially distracting control contest.

Catalysts and monitorables (next 12 months)

• 19 Nov 2026: 1H FY2027 results — Mainland local-currency growth, gross margin, ANZ loss trajectory.

• Outcome/quantification of the Nansha tax enquiry.

• Any further Ng-family filings above 20%, or any Takeovers Code-relevant announcement.

• Pace of buy-backs under the August 2026 mandate.

• Summer 2027 peak-season sell-through for new launches (Jasmine Tea Soy, Da Hong Pao tea, 15g protein).

• June 2027 FY2027 results and dividend (FY2026 final was boosted by the VSL gain — risk of DPS normalisation).

Analyst verdict

Vitasoy has completed the hard part of its post-2021 rehabilitation. The company that ended FY2022 with a HK$159m loss, net current liabilities and no dividend now earns a 15% EBITDA margin, holds HK$703m of net cash, and returns roughly all of its free cash flow through dividends and buy-backs. Management deserves credit for margin discipline: gross margin is up ~380bp over four years and the Mainland unit, once haemorrhaging, earns a 9% underlying operating margin.

The problem is growth. Group revenue has shrunk at a 1.7% CAGR since FY2022 and fell 3% in FY2026, while underlying attributable profit declined 4%. The FY2026 headline beat leaned on a one-off Shanghai land gain. The Mainland — more than half of sales — faces a structurally shrinking general-trade channel, intense tea competition from far larger rivals, and price-sensitive consumers. The new sales leadership produced a better second half, but one half-year does not make a trend. Australia, three years into full ownership, still loses money even before the HK$98m impairment.

At ~HK$6.80 the stock trades at roughly 7–8x EV/EBITDA and 2.4x book, but around 30x adjusted earnings — a valuation that already discounts some recovery. The swing factor is the register: Philip Ng's 20% stake (with ~5% more held by his brother) against the Lo family's ~26% creates genuine strategic optionality, yet no offer has been made and family control, now reinforced by May Lo's elevation to executive role, appears intended to persist.

Our synthesis: a high-quality, financially resilient franchise in a low-growth phase. Fundamental upside requires evidence of sustained Mainland local-currency growth in 1H FY2027; absent that, returns depend on buy-backs and corporate-action speculation. We would characterise the risk/reward as balanced, with positive skew contingent on the November 2026 interim print and any change in shareholder dynamics.